Education
About Us
Working with TipRanks
Follow Us
Captor Therapeutics SA (PL:CTX)
:CTX
CTX Stock Chart & Stats
zł42.20
--
Market closed
zł42.20
--
Day’s Range― - ―
52-Week Rangezł31.20 - zł63.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)12.78K
Market Cap
zł258.19M
Enterprise Valuezł137.39M
Total Cash (Recent Filing)zł48.74M
Total Debt (Recent Filing)zł1.45M
Price to Earnings (P/E)―
Beta0.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,528,709
10 Day Avg. Volume14,277
30 Day Avg. Volume12,784
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.06
Price to Sales (P/S)12.45
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.23
Revenue Forecast (FY)zł24.07M
CTX FAQ
What was Captor Therapeutics SA’s price range in the past 12 months?
Captor Therapeutics SA lowest stock price was zł31.20 and its highest was zł63.00 in the past 12 months.
What is Captor Therapeutics SA’s market cap?
Captor Therapeutics SA’s market cap is zł258.19M.
When is Captor Therapeutics SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Captor Therapeutics SA’s earnings last quarter?
Currently, no data Available
Is Captor Therapeutics SA overvalued?
According to Wall Street analysts Captor Therapeutics SA’s price is currently Overvalued.
Does Captor Therapeutics SA pay dividends?
Captor Therapeutics SA does not currently pay dividends.
What is Captor Therapeutics SA’s EPS estimate?
Captor Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Captor Therapeutics SA have?
Captor Therapeutics SA has 5,528,709 shares outstanding.
What happened to Captor Therapeutics SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Captor Therapeutics SA?
Currently, no hedge funds are holding shares in PL:CTX
Company Description
Captor Therapeutics SA
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.
Technical Analysis
―
Ryvu Therapeutics SA
―
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
―
OncoArendi Therapeutics SA
―
Selvita SA
―